Log in
European Union Approves NOXAFIL(R) (Posaconazole) for Treatment of Invasive Fungal Infections Such As Coccidioidomycosis.
During the clinical trials, NOXAFIL has reportedly demonstrated broad-spectrum activity covering both Yeasts and Moulds that are known to cause various (which could be life threatening especially for those who are immunocompromised or immunosuppressed*) invasive fungal infections.
Now that European Union has authorized Schering- Plough Research Institute to market NOXAFIL in EU, the company will be able to offer this unique anti-fungal oral suspension in not only the current 25 EU member states, but also in Iceland and Norway.
NOXAFIL is often prescribed for invasive diseases such as Aspergillosis, Coccidioidomycosis, Chromoblastomycosis, Fusariosis, and Mycetoma in adult patients with refractory disease, or for the adult patients that do not respond to the common antifungal agents.
The triazole agent was found to be effective for the treatment of fungal infections caused by Fusarium (responsible for chromoblastomycosis and mycetoma) and Coccidioides. It must be noted, however, that Posaconazole should not be used in conjunction with ergot alkaloids, CYP 3A4, and HMG-CoA reductase inhibitors.
FDA Approved : Interactive Breathing Device
A Natural, Relaxing and Clinically Proven Way to Manage Blood Pressure
Helps You Breath Easy and Lowers Your Blood Pressure
RESPeRATE